Recombinant factor IX secreted by transduced human keratinocytes is biologically active

British Journal of Haematology

Volumn 95, Issue 3, 1996, Pages 561-563

  Gerrard, A J ^a   Austen, D E G ^b   Brownlee, G G ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Factor IX; Gene therapy; Haemophilia B; Keratinocytes; Retrovirus

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 9; UNCLASSIFIED DRUG;

ARTICLE; ASSAY; CONTROLLED STUDY; GENE THERAPY; HEMOPHILIA B; HUMAN; HUMAN CELL; KERATINOCYTE; PRIORITY JOURNAL; RETROVIRUS;

EID: 0029955012     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1996.d01-1923.x     Document Type: Article

References (12)

1. Anson, D.S., Austen, D.E.G. & Brownlee, G.G. (1985) Expression of active human clotting factor IX from recombinant DNA clones in mammalian cells. Nature, 315, 683-685.
2. Austen, D.E.G. & Rhymes, I.L. (1975) A laboratory Manual of Blood Coagulation. Blackwell Scientific Publications, Oxford.
3. Axelrod, J.H., Read, M.S., Brinkhous, K.M. & Verma, I.M. (1990) Phenotypic correction of factor IX deficiency in skin fibroblasts of hemophilic dogs. Proceedings of the National Academy of Sciences of the United States of America, 87, 5173-5177.
4. Berrettini, M., Iorio, P., Nenci, G.G., Arcieri, P. & Mariani, G. (1994) Subcutaneous factor IX administration to patients with hemophilia B. American Journal of Haematology, 47, 61-62.
5. Brownlee, G.G. (1995) Prospects for gene therapy of haemophilia A and B. British Medical Bulletin, 51, 91-105.
6. Drake, T.A., Morrissey, J.H. & Edgington, T.S. (1989) Selective cellular expression of tissue factor in human tissues. American Journal of Pathology, 134, 1087-1097.
7. Gerrard, A.J., Austen, D.E.G. & Brownlee, G.G. (1992) Subcutaneous injection of factor IX for the treatment of haemophilia B. British Journal of Haematology, 81, 610-613.
8. Gerrard, A.J., Hudson, D.L., Brownlee, G.G. & Watt, F.M. (1993) Towards gene therapy for haemophilia B using primary human keratinocytes. Nature Genetics, 3, 180-183.
9. Hao, Q-L., Malik, P., Salazar, R., Tang, H., Cordon, E.M. & Kohn, D.B. (1995) Expression of biologically active human factor IX in human hematopoietic cells after retroviral vector-mediated gene transduction. Human Gene Therapy, 6, 873-880.
10. White, G., Shapiro, A., Ragni, M., Kaye, J., Tubridy, K., McCarthy, K. & Courter, S. (1995) Phase I/II pharmacokinetics, safely and efficacy data of recombinant human factor IX in previously treated patients with hemophilia B. (Abstract). Blood, 86, (Suppl.). 193A.
11. Yao, S.-N. & Kurachi, K. (1992) A simple treatment of serum for precise determination of recombinant factor IX in the culture medium. Biofeedback, 12, 525-526.
12. Yoshioka, A., Giddings, J.C., Thomas, J.E., Fujimura, Y. & Bloom, A.R. (1985) Immunoassays of factor IX antigen using monoclonal antibodies. British Journal of Haematology, 59, 265-275.